CD300a expression is modulated in atopic dermatitis and could influence the inflammatory response
Laila Karra
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorRoopesh Singh Gangwar
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorPier Giorgio Puzzovio
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorNanna Fyhrquist
Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland
Search for more papers by this authorYael Minai-Fleminger
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorNadine Landolina
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorHans-Uwe Simon
Institute of Pharmacology, University of Bern, Bern, Switzerland
Search for more papers by this authorHarri Alenius
Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland
Search for more papers by this authorVera Leibovici
Department of Dermatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorDagmar Simon
Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Search for more papers by this authorCorresponding Author
Francesca Levi-Schaffer
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Correspondence
Francesca Levi-Schaffer, Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.
Email: [email protected]
Search for more papers by this authorLaila Karra
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorRoopesh Singh Gangwar
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorPier Giorgio Puzzovio
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorNanna Fyhrquist
Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland
Search for more papers by this authorYael Minai-Fleminger
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorNadine Landolina
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Search for more papers by this authorHans-Uwe Simon
Institute of Pharmacology, University of Bern, Bern, Switzerland
Search for more papers by this authorHarri Alenius
Department of Bacteriology and Immunology, Medicum, University of Helsinki, Helsinki, Finland
Search for more papers by this authorVera Leibovici
Department of Dermatology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Search for more papers by this authorDagmar Simon
Department of Dermatology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
Search for more papers by this authorCorresponding Author
Francesca Levi-Schaffer
Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel
Correspondence
Francesca Levi-Schaffer, Pharmacology and Experimental Therapeutics Unit, School of Pharmacy, Faculty of Medicine, Institute for Drug Research, The Hebrew University of Jerusalem, Jerusalem, Israel.
Email: [email protected]
Search for more papers by this author
Supporting Information
| Filename | Description |
|---|---|
| all13724-sup-0001-SupInfo.docxWord document, 1.1 MB |
Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
REFERENCES
- 1Zenarruzabeitia O, Vitalle J, Eguizabal C, Simhadri VR, Borrego F. The biology and disease relevance of CD300a, an inhibitory receptor for phosphatidylserine and phosphatidylethanolamine. J Immunol. 2015; 194(11): 5053-5060.
- 2Gangwar RS, Landolina N, Arpinati L, Levi-Schaffer F. Mast cell and eosinophil surface receptors as targets for anti-allergic therapy. Pharmacol Ther. 2017; 170: 37-63.
- 3Weidinger S, Novak N. Atopic dermatitis. Lancet. 2016; 387(10023): 1109-1122.
- 4Schultze JL, Schmieder A, Goerdt S. Macrophage activation in human diseases. Semin Immunol. 2015; 27(4): 249-256.
- 5Luci C, Gaudy-Marqueste C, Rouzaire P, et al. Peripheral natural killer cells exhibit qualitative and quantitative changes in patients with psoriasis and atopic dermatitis. Br J Dermatol. 2012; 166(4): 789-796.
- 6Karra L, Singh Gangwar R, Shamri R, et al. Leukocyte CD300a contributes to the resolution of murine allergic inflammation. J Immunol. 2018; 201(10): 2998-3005.
- 7Nissim Ben Efraim AH, Karra L, Ben-Zimra M, Levi-Schaffer F. The inhibitory receptor CD300a is up-regulated by hypoxia and GM-CSF in human peripheral blood eosinophils. Allergy. 2013; 68(3): 397-401.
- 8Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J Allergy Clin Immunol. 2017; 139(4S): S65-S76.
- 9Egners A, Erdem M, Cramer T. The response of macrophages and neutrophils to hypoxia in the context of cancer and other inflammatory diseases. Mediators Inflamm. 2016; 2016: 2053646.
Citing Literature
